EP3033150A4 - Administration de karénitécine pour traiter un cancer avancé de l'ovaire, y compris des sous-types d'adénocarcinomes chimio-résistants et/ou mucineux - Google Patents

Administration de karénitécine pour traiter un cancer avancé de l'ovaire, y compris des sous-types d'adénocarcinomes chimio-résistants et/ou mucineux Download PDF

Info

Publication number
EP3033150A4
EP3033150A4 EP14836702.2A EP14836702A EP3033150A4 EP 3033150 A4 EP3033150 A4 EP 3033150A4 EP 14836702 A EP14836702 A EP 14836702A EP 3033150 A4 EP3033150 A4 EP 3033150A4
Authority
EP
European Patent Office
Prior art keywords
karenitecin
administration
resistant
types
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14836702.2A
Other languages
German (de)
English (en)
Other versions
EP3033150A1 (fr
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of EP3033150A1 publication Critical patent/EP3033150A1/fr
Publication of EP3033150A4 publication Critical patent/EP3033150A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14836702.2A 2013-08-13 2014-08-10 Administration de karénitécine pour traiter un cancer avancé de l'ovaire, y compris des sous-types d'adénocarcinomes chimio-résistants et/ou mucineux Withdrawn EP3033150A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865360P 2013-08-13 2013-08-13
PCT/US2014/050463 WO2015023551A1 (fr) 2013-08-13 2014-08-10 Administration de karénitécine pour traiter un cancer avancé de l'ovaire, y compris des sous-types d'adénocarcinomes chimio-résistants et/ou mucineux

Publications (2)

Publication Number Publication Date
EP3033150A1 EP3033150A1 (fr) 2016-06-22
EP3033150A4 true EP3033150A4 (fr) 2017-06-28

Family

ID=52468603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14836702.2A Withdrawn EP3033150A4 (fr) 2013-08-13 2014-08-10 Administration de karénitécine pour traiter un cancer avancé de l'ovaire, y compris des sous-types d'adénocarcinomes chimio-résistants et/ou mucineux

Country Status (2)

Country Link
EP (1) EP3033150A4 (fr)
WO (3) WO2015023552A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202643B2 (en) 2011-10-31 2019-02-12 University Of Utah Research Foundation Genetic alterations in glioma
US20180122507A1 (en) * 2015-04-14 2018-05-03 University Of Utah Research Foundation Genetic alterations in ovarian cancer
CN105198790B (zh) * 2015-04-20 2018-02-16 范国煌 促进双阴性t细胞体外增殖的四环化合物
ES2905208T3 (es) * 2016-01-27 2022-04-07 Fraunhofer Ges Forschung Medios y métodos para la estadificación, tipificación y tratamiento de una enfermedad cancerosa
CN107058315B (zh) 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
EP3642351A1 (fr) * 2017-06-20 2020-04-29 Nantomics, LLC Utilisation de l'expression d'arn en circulation acellulaire (arncf) de pd-l1 et ercc1 dans le plasma pour suivre la réponse à un traitement du cpnpc
CN113461952B (zh) * 2021-06-30 2022-07-01 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种活性氧响应型自降解聚合物及其制备方法与应用
CN118103949A (zh) * 2021-09-15 2024-05-28 英飞凌科技有限责任公司 将sonos集成至hkmg流中的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (fr) * 2004-04-27 2005-12-01 Wellstat Biologics Corporation Traitement de cancers utilisant des virus et des camptothécines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968607B1 (fr) * 2005-12-02 2014-01-15 Nabil Habib Lab Traitement du cancer et d'autres maladies
US9023805B2 (en) * 2010-09-16 2015-05-05 Bionumerik Pharmaceuticals, Inc. Increasing cancer patient survival time by administration of dithio-containing compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (fr) * 2004-04-27 2005-12-01 Wellstat Biologics Corporation Traitement de cancers utilisant des virus et des camptothécines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNEMARIE H. VAN HATTUM ET AL: "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 2, 15 October 2000 (2000-10-15), pages 260 - 266, XP055007980, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q *
MUNSTER PAMELA N ET AL: "Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 20, no. 11, November 2011 (2011-11-01), pages 1565 - 1574, XP002766330 *
NAUMANN R WENDEL ET AL: "Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 71, no. 11, 1 January 2011 (2011-01-01), pages 1397 - 1412, XP009165133, ISSN: 0012-6667, DOI: 10.2165/11591720-000000000-00000 *
See also references of WO2015023551A1 *

Also Published As

Publication number Publication date
WO2015023551A1 (fr) 2015-02-19
WO2015023552A1 (fr) 2015-02-19
WO2015023553A2 (fr) 2015-02-19
WO2015023553A3 (fr) 2015-04-23
EP3033150A1 (fr) 2016-06-22

Similar Documents

Publication Publication Date Title
EP3558324A4 (fr) Agonistes dinucléotidiques cycliques de sting pour le traitement du cancer
EP3033150A4 (fr) Administration de karénitécine pour traiter un cancer avancé de l&#39;ovaire, y compris des sous-types d&#39;adénocarcinomes chimio-résistants et/ou mucineux
EP3119908A4 (fr) Détermination de l&#39;agressivité d&#39;un cancer, de son pronostic et de sa sensibilité à un traitement
EP3062808A4 (fr) Traitement d&#39;un cancer de la prostate métastasique
EP3268465A4 (fr) Méthodes de traitement du cancer au moyen de cellules t activées
EP3197518A4 (fr) Préparation médicamenteuse et dispositifs, méthodes et systèmes de traitement
EP3071209A4 (fr) Utilisation d&#39;un agoniste de sting en tant que traitement anti-cancéreux
EP3004877A4 (fr) Compositions et procédés d&#39;identification, d&#39;évaluation, de prévention et de traitement du cancer en utilisant des isoformes pd-l1
EP3076977A4 (fr) Polythérapie pour le traitement du cancer
EP3076972A4 (fr) Traitement du cancer avec une association de plinabuline et de taxane
EP3033079A4 (fr) Méthodes de traitement d&#39;un cancer amplifié par her2
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
EP3024375A4 (fr) Dispositif médical et ses méthodes d&#39;utilisation
EP3432888A4 (fr) Traitement du cancer avec tg02
WO2014116833A3 (fr) Compositions et procédés de détection de néoplasie
EP3307329A4 (fr) Traitement et diagnostic du cancer
WO2014138364A3 (fr) Méthodes de traitement et de prévention de la résistance à un médicament d&#39;un cancer
EP3180000A4 (fr) Diagnostic et thérapie du cancer
EP2996721A4 (fr) Méthodes et compositions pour pronostiquer, diagnostiquer et traiter un cancer exprimant adam8
EP3004396A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3007557A4 (fr) Préparation de (s,s)-sécoisolaricirésinol diglucoside et de (r,r)-sécoisolaricirésinol diglucoside
EP3062790A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3008212A4 (fr) Méthodes de traitement du cancer
EP3364987A4 (fr) Pronostic et traitement de carcinomes de cellules squameuses
EP3011013A4 (fr) Procédé pour le traitement d&#39;un cancer de l&#39;ovaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAUSHEER, FREDERICK H.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20170130BHEP

Ipc: A61K 31/185 20060101ALI20170130BHEP

Ipc: A61K 31/4745 20060101AFI20170130BHEP

Ipc: A61P 35/00 20060101ALI20170130BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170526

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20170519BHEP

Ipc: A61K 31/185 20060101ALI20170519BHEP

Ipc: A61K 31/4745 20060101AFI20170519BHEP

Ipc: A61P 35/00 20060101ALI20170519BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20170614BHEP

Ipc: A61K 31/185 20060101ALI20170614BHEP

Ipc: A61K 31/4745 20060101AFI20170614BHEP

Ipc: A61K 45/06 20060101ALI20170614BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CROWN BIOSCIENCE, INC.

17Q First examination report despatched

Effective date: 20190405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190817